Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid.

Calabrese F, Luoni A, Guidotti G, Racagni G, Fumagalli F, Riva MA.

Psychopharmacology (Berl). 2013 Mar;226(1):101-12. doi: 10.1007/s00213-012-2900-0. Epub 2012 Oct 24.

PMID:
23093383
2.

Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress.

Fumagalli F, Calabrese F, Luoni A, Bolis F, Racagni G, Riva MA.

Int J Neuropsychopharmacol. 2012 Mar;15(2):235-46. doi: 10.1017/S1461145711000150. Epub 2011 Feb 24.

PMID:
21349227
3.

Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats.

Luoni A, Hulsken S, Cazzaniga G, Racagni G, Homberg JR, Riva MA.

Int J Neuropsychopharmacol. 2013 Jul;16(6):1319-30. doi: 10.1017/S1461145712001332. Epub 2012 Nov 20.

PMID:
23164505
4.

Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment.

Luoni A, Rocha FF, Riva MA.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Apr 3;50:94-101. doi: 10.1016/j.pnpbp.2013.12.008. Epub 2013 Dec 18.

PMID:
24361635
5.

Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence.

Luoni A, Berry A, Calabrese F, Capoccia S, Bellisario V, Gass P, Cirulli F, Riva MA.

Eur Neuropsychopharmacol. 2014 Jun;24(6):986-95. doi: 10.1016/j.euroneuro.2013.12.010. Epub 2013 Dec 30.

PMID:
24440552
6.

Update on the development of lurasidone as a treatment for patients with acute schizophrenia.

Yasui-Furukori N.

Drug Des Devel Ther. 2012;6:107-15. doi: 10.2147/DDDT.S11180. Epub 2012 May 8. Review.

7.

The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.

Tarazi FI, Riva MA.

Expert Opin Drug Discov. 2013 Oct;8(10):1297-307. doi: 10.1517/17460441.2013.815163. Epub 2013 Jul 10. Review.

PMID:
23837554
8.

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.

Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M.

J Pharmacol Exp Ther. 2010 Jul;334(1):171-81. doi: 10.1124/jpet.110.167346. Epub 2010 Apr 19.

10.

Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression.

Corena-McLeod Mdel P, Oliveros A, Charlesworth C, Madden B, Liang YQ, Boules M, Shaw A, Williams K, Richelson E.

Brain Res. 2008 Oct 3;1233:8-19. doi: 10.1016/j.brainres.2008.07.021. Epub 2008 Jul 15.

PMID:
18657526
11.

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2011 Feb;65(2):189-210. doi: 10.1111/j.1742-1241.2010.02587.x. Epub 2010 Dec 3. Review.

PMID:
21129135
12.

Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity.

Fumagalli F, Molteni R, Roceri M, Bedogni F, Santero R, Fossati C, Gennarelli M, Racagni G, Riva MA.

J Neurosci Res. 2003 Jun 1;72(5):622-8.

PMID:
12749027
13.

Lurasidone (latuda®): an atypical antipsychotic.

Nolan SF, Roman MW.

Issues Ment Health Nurs. 2012 May;33(5):342-3. doi: 10.3109/01612840.2012.669025. Review.

PMID:
22545643
14.

Lurasidone exerts antidepressant properties in the chronic mild stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex.

Luoni A, Macchi F, Papp M, Molteni R, Riva MA.

Int J Neuropsychopharmacol. 2014 Oct 31;18(4). pii: pyu061. doi: 10.1093/ijnp/pyu061.

15.

New model of action for mood stabilizers: phosphoproteome from rat pre-frontal cortex synaptoneurosomal preparations.

Corena-McLeod M, Walss-Bass C, Oliveros A, Gordillo Villegas A, Ceballos C, Charlesworth CM, Madden B, Linser PJ, Van Ekeris L, Smith K, Richelson E.

PLoS One. 2013 May 14;8(5):e52147. doi: 10.1371/journal.pone.0052147. Print 2013.

16.

[Towards better non-selectivity: the role of 5-HT7 receptors in therapeutic efficacy of a second-generation antipsychotic - lurasidone].

Bieńkowski P, Dudek D, Samochowiec J.

Psychiatr Pol. 2015 Mar-Apr;49(2):243-53. doi: 10.12740/PP/38250. Review. Polish.

17.

Long-Term duloxetine treatment normalizes altered brain-derived neurotrophic factor expression in serotonin transporter knockout rats through the modulation of specific neurotrophin isoforms.

Calabrese F, Molteni R, Cattaneo A, Macchi F, Racagni G, Gennarelli M, Ellenbroek BA, Riva MA.

Mol Pharmacol. 2010 May;77(5):846-53. doi: 10.1124/mol.109.063081. Epub 2010 Feb 16.

18.

Neuronal plasticity: a link between stress and mood disorders.

Calabrese F, Molteni R, Racagni G, Riva MA.

Psychoneuroendocrinology. 2009 Dec;34 Suppl 1:S208-16. doi: 10.1016/j.psyneuen.2009.05.014. Epub . Review.

PMID:
19541429
19.

The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.

Yuen EY, Li X, Wei J, Horiguchi M, Meltzer HY, Yan Z.

Mol Pharmacol. 2012 Feb;81(2):113-9. doi: 10.1124/mol.111.076141. Epub 2011 Nov 9.

20.

Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.

Citrome L.

Postgrad Med. 2011 Mar;123(2):153-62. doi: 10.3810/pgm.2011.03.2273. Review.

PMID:
21474903
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk